Here are six things to know about the report:
1. The full-year revenue is $22 million to $24 million, based on current expectations.
2. Amedica reported strong sales and acceptance of the core silicon nitride material.
3. There was a “softer” demand for the company’s metals products during the fourth quarter.
4. Amedica received compiled data from a blinded, randomized trail comparing cervical fusion clinical and radiographic outcomes for its proprietary porous silicon nitride to plastic interbody spacers made of PEEK filled with bone autograft. The company will announce clinical results in January 2015.
5. The data is expected to support Amedica’s efforts to receive 510(k) clearance for CASCADE, which the clinical study examined.
6. The clinical results will also enable commercialization for the composite silicon nitride interbody device next year, which could decrease the cost and complexity of orthopedic procedures.
“These results, in tandem with the recent strengthening of our balance sheet, underscore our commitment to growing the core silicon nitride business and successfully expanding our OEM strategy,” said Sonny Bal, MD, Chairman and CEO of Amedica.
More articles on spine surgery:
4 spine, neurosurgery practice expansions
5 key trends on spinal fusion BMP use after 2008
Spine surgery for ‘Generation Me’: Will customization lead to better outcomes?
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
